The round, which brings total funding to $160m, was led by Founders Fund with participation from existing investors 8VC and Menlo Ventures.
The company intends to use the new funds to accelerate CRISPR capabilities for rapid and precise genome engineering in applications such as cell and gene therapies.
Led by Paul Dabrowski, co-founder and CEO, Synthego has developed an automated, full-stack genome engineering platform that leverages automation, bioinformatics, and machine learning to enable access to CRISPR to accelerate basic scientific discovery, uncover critical disease cures and develop novel synthetic biology applications.
In conjunction with the funding, the company announced that Dr. Matthew Porteus will join its advisory board. Dr. Porteus is a Professor at Stanford University, physician at the Lucille Packard Children’s Hospital, and pioneer of cell-based therapies, a scientific co-founder of CRISPR Therapeutics, a company focused on developing gene-editing based therapeutics.
He joins industry leaders Sir Andrew Witty, CEO of Optum, and Dr. Jennifer Doudna, co-inventor of CRISPR, on the advisory board.
FinSMEs
23/10/2018